Blood biomarkers in Down syndrome : Facilitating Alzheimer's disease detection and monitoring
Petersen, Melissa E. (University of North Texas Health Science Center (Texas, Estats Units d'Amèrica))
Flores-Aguilar, Lisi (University of California (Estats Units d'Amèrica))
Head, Elizabeth (University of California (Estats Units d'Amèrica))
Montoliu-Gaya, Laia (Sahlgrenska Academy at the University of Gothenburg (Göteborg, Suècia))
Strydom, Andre (King's College London)
Pape, Sarah E. (King's College London)
Fortea, Juan (Institut de Recerca Sant Pau)
Ashton, Nicholas J. (Stavanger University Hospital (Stavanger, Noruega))
Udeh-Momoh, Chinedu (Aga Khan University (Nairobi, Kenya))
O'Bryant, Sid E. (University of North Texas Health Science Center (Texas, Estats Units d'Amèrica))
German, Dwight (University of Texas Southwestern Medical Center (Texas, Estats Units d'Amèrica))
Despa, Florin (University of Kentucky (Estats Units d'Amèrica))
Mapstone, Mark (University of California (Estats Units d'Amèrica))
Zetterberg, Henrik (University of Wisconsin-Madison (Estats Units d'Amèrica))
Universitat Autònoma de Barcelona

Data:	2025
Resum:	Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer's Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. This perspective highlights the current status of this effort. Overall, amyloid (A), tau (T), and neurodegeneration (AT[N]) blood-based biomarkers have been shown to increase with disease pathology for individuals with DS. Phosphorylated tau biomarkers (p-tau217, p-tau181) have been consistently shown to track disease progression for DS-AD and are likely good candidates for use in clinical settings. Biomarkers of inflammation (glial fibrillary acidic protein) also show promise; however, additional work is needed. Findings from stability work of blood-based biomarkers conducted among non-DS also support the potential longitudinal utility of biomarkers such as neurofilament light chain and p-tau181 in DS. Gaps in our knowledge are highlighted, and a potential role for sex differences in biomarker outcomes is noted, along with recommendations for determining the appropriate context of use when translating biomarkers into clinical applications. Highlights: An overview of blood-based biomarkers for Alzheimer's disease (AD) was provided for consideration of their utility among individuals with Down syndrome when looking toward potential clinical applications. Longitudinal stability of many blood biomarkers and improvement in detection sensitivity make blood such as plasma a viable source for exploring AD pathology. Variability in reviewed findings regarding the application of blood biomarkers highlights the importance of understanding and defining the appropriate context of use, particularly when translating them into clinical practice.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Alzheimer's disease ; Down syndrome ; Amyloid ; Biomarkers ; Neurodegeneration ; Tau
Publicat a:	Alzheimer's & dementia, Vol. 21 Núm. 1 (january 2025) , p. e14364, ISSN 1552-5279

DOI: 10.1002/alz.14364
PMID: 39535517

11 p, 307.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats